Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma Poster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback